Stock Traders Purchase Large Volume of Veru Call Options (NASDAQ:VERU)

This article was originally published on this site

Veru Inc. (NASDAQ:VERU) saw some unusual options trading activity on Thursday. Traders bought 42,928 call options on the company. This represents an increase of 2,023% compared to the average volume of 2,022 call options.

A number of research analysts have recently issued reports on the stock. Oppenheimer boosted their price target on shares of Veru from $9.00 to $19.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 16th. Cantor Fitzgerald boosted their price target on shares of Veru from $6.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, December 14th. Brookline Capital Management boosted their price target on shares of Veru from $13.00 to $17.00 in a research note on Monday, December 14th. HC Wainwright boosted their price target on shares of Veru from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, December 10th. Finally, Zacks Investment Research lowered shares of Veru from a “buy” rating to a “hold” rating in a research note on Thursday, December 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $13.15.

In other Veru news, CEO Mitchell Shuster Steiner sold 250,000 shares of Veru stock in a transaction on Wednesday, December 16th. The shares were sold at an average price of $9.69, for a total value of $2,422,500.00. Following the transaction, the chief executive officer now directly owns 7,184,767 shares in the company, valued at $69,620,392.23. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider K Gary Barnette sold 100,000 shares of Veru stock in a transaction on Wednesday, December 16th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. The disclosure for this sale can be found here. Insiders own 26.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in shares of Veru by 4.1% in the third quarter. State Street Corp now owns 553,976 shares of the company’s stock valued at $1,451,000 after purchasing an additional 21,802 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Veru by 5.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 389,663 shares of the company’s stock valued at $1,021,000 after purchasing an additional 20,591 shares in the last quarter. Kestra Private Wealth Services LLC purchased a new stake in shares of Veru in the third quarter valued at about $1,592,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Veru by 703.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 122,171 shares of the company’s stock valued at $409,000 after purchasing an additional 106,971 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Veru by 489.7% in the second quarter. Bank of New York Mellon Corp now owns 132,695 shares of the company’s stock valued at $443,000 after purchasing an additional 110,194 shares in the last quarter. 23.32% of the stock is currently owned by institutional investors.

VERU stock traded down $3.20 during trading on Friday, reaching $11.08. 112,134 shares of the company were exchanged, compared to its average volume of 3,917,506. The company has a market cap of $796.73 million, a P/E ratio of -39.68 and a beta of 0.71. Veru has a 52-week low of $2.30 and a 52-week high of $14.59. The stock’s 50 day moving average price is $9.05 and its 200 day moving average price is $4.53.

Veru (NASDAQ:VERU) last released its quarterly earnings data on Tuesday, December 8th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.07. Veru had a negative net margin of 44.55% and a negative return on equity of 23.72%. The firm had revenue of $11.75 million for the quarter, compared to the consensus estimate of $10.64 million. Equities analysts expect that Veru will post -0.24 earnings per share for the current fiscal year.

About Veru

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Further Reading: Which market index is the best?

Receive News & Ratings for Veru Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Veru and related companies with MarketBeat.com’s FREE daily email newsletter.